| Name | Title | Contact Details |
|---|
BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.
B-Bridge International is a Cupertino, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GlobeImmune is a Louisville, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IgGenix is an early-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake`s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau.
Better products. Better service. MOLECULAR DESIGNS Molecular Designs is a team of doctors and scientists working to advance molecular diagnostics. We do this by developing, producing, and supplying multiplex assays for molecular testing ...